. All the batches of heparinised tubes tested showed significantly (P<0·05) higher calcium levels than the plain glass tubes used as controls, and gross elevations of calcium concentration were observed with Sherwood Medical batches 86218 and 86247.
Disc1mion
We concluded that heparinised tubes from batches 86218 and 86247 contained clinically significant calcium contamination, and informed the manufacturers and the Department of Health and Social Security (DHSS). The manufacturers acted promptly to limit distribution of the tubes, and the DHSS wrote directly
We wish to report the finding of significant calcium contamination in two batches of commercial lithium heparin blood collection tubes (LH1O; Sherwood Medical Ltd, Crawley, West Sussex, UK), which resulted in misleadingly high plasma calcium levels.
In mid-November 1986 we became aware of an increased frequency of slightly elevated plasma calcium results from the workload on our Beckman Astra 8 analyser (cresolphthalein complexone method). On checking a number of these results using serum samples collected at the same time for other tests, we were disturbed to observe markedly discrepant results (Table 1) .
We checked these findings by adding 1·0 mL of commercial quality control serum (Versatol Lock-In Calibrate, General Diagnostics, New Jersey, USA) to samples of tubes from different batch numbers and from other manufacturers, and measuring the calcium concentration using a continuous flow method based on a cresolphthalein complexone procedure. to hospitals which had received these batches of tubes to warn them of the defect. Investigation by the manufacturer traced the problem to a contaminated batch of lithium heparin obtained from a West German supplier.
It can be seen from Table 2 that the interference is up to 0·7 mmol/L when 1 mL of sample is added to a 10 mL tube, but willclearly be <0·1 mmollL if the tube is filled to the 10 mL line. However. in common with many other laboratories. we frequently receive tubes that are underfilled, and clinically significant errors may result in such cases (e.g. patients 1-3 above).
The possibility of artefactually raised plasma calcium levels due to contaminated anticoagulant must be added to the list of potential sources of error in blood collection. We are aware of a similar incident some years ago involving tubes from another manufacturer, so the problem is not an isolated occurence. The British Standard for such tubes (BS 4851) does not specify maximum levels for calcium content, and we have urged that this be rectified when the Standard is revised. In the meantime, laboratories may wish to perform their own checks on heparin tubes, or to seek detailed information from the relevant manufacturer.
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